Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Expert Report on novelties in the management of gynaecological malignancies from ASCO 2022

Reporting from ASCO 2022 Annual Meeting in Chicago, Domenica LORUSSO features the results from 3 trials in Gynaecological Malignancies.
She details findings from the innovaTV-205 trial testing the first-line tisotumab vedotin plus pembrolizumab in recurrent or metastatic Cervical Cancer. She also discusses the results from the MITO 23 study evaluating trabectedin vs clinician's choice of chemotherapy in recurrent Ovarian Cancer, and further comments the results from the ATHENA-MONO trial assessing maintenance rucaparib vs placebo following first-line chemotherapy in Ovarian Cancer.

This video was supported with educational grants from Bayer Healthcare, Novartis and Roche.
The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.